Med BioGene, Precision Therapeutics Settle Legal Battle with Signal Genetics | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene today said that it and its commercial partner, Precision Therapeutics, have settled litigation with Signal Genetics and its Respira Health subsidiary, ending a dispute over an alleged breach of contract that began more than two years ago.

Under the terms of the agreement announced today, Precision will make an undisclosed payment to Signal Genetics and Respira on or by Jan. 6, 2014. Following the payment, Signal Genetics and Respira will dismiss and withdraw all of their legal claims made against Med BioGene and Precision.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.